The European Biopharmaceutical Enterprises (EBE) has appointed Eduardo Bravo as president of its board of directors for the 2016-2018 term.
Bravo graduates to the leadership role of the European trade association from his previous position as its vice president.
He said: “This is a very exciting time at the EBE. We are well positioned to help new initiatives and cutting-edge technologies advance biopharmaceutical pipelines toward eventual solutions for difficult-to-treat conditions and diseases.
“It is a pleasure to be working with such a dedicated group of senior industry leaders to support emerging sciences in the search of therapeutic solutions.”
Bravo has over 25 years of experience in the biopharmaceutical industry, and is a member of the executive committee of the Alliance for Regenerative Medicine (ARM).
He currently serves as chief executive officer of TiGenix, a biopharma company based in Belgium, and prior to this served as Cellerix’s chief executive officer between 2006 and 2011.
Barbara Freischem, EBE’s executive director, said: “Mr Bravo brings so much to our organisation.
“Coming from the field of advanced therapies, he helps bridge the gap between the lab and personalised medicines within a thriving and innovative ecosystem.”